Comparative Pharmacology
Head-to-head clinical analysis: INREBIC versus REVUFORJ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INREBIC versus REVUFORJ.
INREBIC vs REVUFORJ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor. It inhibits JAK2 and its mutant forms, including JAK2V617F, leading to reduced phosphorylation of signal transducer and activator of transcription (STAT) proteins and decreased proliferation of abnormal hematopoietic cells.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
100 mg orally twice daily continuously until disease progression or unacceptable toxicity.
Oral, 500 mg twice daily.
None Documented
None Documented
Terminal elimination half-life approximately 14 hours; supports twice-daily dosing for steady-state attainment within 3 days
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Fecal (77.6% as metabolites, 2.2% as unchanged drug); renal (8.5% as metabolites, <1% as unchanged drug)
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Category C
Category C
JAK Inhibitor
JAK Inhibitor